National Academies Press: OpenBook
« Previous: Appendix A: Workshop Agenda
Suggested Citation:"Appendix B: Workshop Attendees." Institute of Medicine. 2014. Caffeine in Food and Dietary Supplements: Examining Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18607.
×
Page 175
Suggested Citation:"Appendix B: Workshop Attendees." Institute of Medicine. 2014. Caffeine in Food and Dietary Supplements: Examining Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18607.
×
Page 176
Suggested Citation:"Appendix B: Workshop Attendees." Institute of Medicine. 2014. Caffeine in Food and Dietary Supplements: Examining Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18607.
×
Page 177
Suggested Citation:"Appendix B: Workshop Attendees." Institute of Medicine. 2014. Caffeine in Food and Dietary Supplements: Examining Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18607.
×
Page 178
Suggested Citation:"Appendix B: Workshop Attendees." Institute of Medicine. 2014. Caffeine in Food and Dietary Supplements: Examining Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18607.
×
Page 179
Suggested Citation:"Appendix B: Workshop Attendees." Institute of Medicine. 2014. Caffeine in Food and Dietary Supplements: Examining Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18607.
×
Page 180
Suggested Citation:"Appendix B: Workshop Attendees." Institute of Medicine. 2014. Caffeine in Food and Dietary Supplements: Examining Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18607.
×
Page 181
Suggested Citation:"Appendix B: Workshop Attendees." Institute of Medicine. 2014. Caffeine in Food and Dietary Supplements: Examining Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18607.
×
Page 182
Suggested Citation:"Appendix B: Workshop Attendees." Institute of Medicine. 2014. Caffeine in Food and Dietary Supplements: Examining Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18607.
×
Page 183
Suggested Citation:"Appendix B: Workshop Attendees." Institute of Medicine. 2014. Caffeine in Food and Dietary Supplements: Examining Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18607.
×
Page 184

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

B Workshop Attendees Naman Ahluwalia Patrizia Barone Centers for Disease Control and Unilever Prevention Maureen Beach Rend Al-Mondhiry ABA Council for Responsible Nutrition Stephanie Beasley Inside Health Policy Joan Apgar The Hershey Co. Michael Beckelic Meda Consumer Healthcare Inc. Steven Armstrong Campbell Soup Co. Nadine Bewry U.S. Department of Food and Bob Arnot Drug Administration (FDA) Monster Energy Co. Heidi Bialk Arti Arora PepsiCo, Inc. The Coca-Cola Co. Sonya Billiard MaryJoy Ballantyne Health Canada Covington & Burling Hope Bilyk James Bangasser Rosalind Franklin University of American Beverage Association Medicine and Science (ABA) 175

176 CAFFEINE IN FOOD AND DIETARY SUPPLEMENTS Adrienne Black Robert Burns Grocery Manufacturers GMA Association (GMA) Kaitlyn Buss Stephen Boehm Story Partners Purdue University Kathryn Camp Michael Bolger NIH Exponent Jessica Campbell Sarah Botha General Mills, Inc. Federal Trade Commission Susan Carlson Trudi Boyd FDA Story Partners Murray Carpenter Rosalind Breslow Freelance National Institutes of Health (NIH) Kellie Casavale U.S. Department of Health and Lauren Brookmire Human Services (HHS) FDA Bruce Charash Whitney Brown Academy of Nutrition and Sonya Clay Dietetics (AND) American Academy of Pediatrics Jen Brulc General Mills, Inc. Amy Clewell AIBMR Life Sciences, Inc. Leon Bruner GMA Ashley Cook Health Canada Brittany Bugbee University of Maryland Michele Corash Morrison & Foerster LLP Shelly Burgess FDA

APPENDIX B 177 Mark Corey Robert Earl Green Mountain Coffee The Coca-Cola Co. Roasters, Inc. Marianne Smith Edge Heather Nelson Cortes IFIC Optimum Nutrition Anna Edney Jaclyn Crouch Bloomberg NIH Theresa Eisenman Cindy Davis FDA NIH Dave Ellis Tom Davis SportsRD Monster Energy Co. John Endres Paul Dechary AIBMR Life Sciences, Inc. Monster Energy Co. Cecilia Wilkinson Enns Brady Dennis U.S. Department of Agriculture Washington Post (USDA) Joseph DeRupo Ilene Eskenazi National Coffee Association Daniel Fabricant Patricia Deuster FDA Uniformed Services University of the Health Sciences Suzanne Fitzpatrick (USUHS) FDA Candace Doepker Jennifer Folliard ToxStrategies, Inc. Academy of Nutrition and Dietetics George Dunaif GMA Michael Forman MHFEDMD, Inc. Johanna Dwyer NIH Ellen Fried New York State Attorney General’s Office

178 CAFFEINE IN FOOD AND DIETARY SUPPLEMENTS Joel Geerling Kasey Heintz Harvard Medical School FDA Francesca Gessber Eric Hentges San Francisco City Attorney International Life Sciences Institute (ILSI) Kevin Goldberg Steve Hertzler Mark Gottlieb Abbott Nutrition Northeastern University Regina Hildwine Amanda Grady GMA FDA Nicole Hines James Griffiths International Food Information CRN-International Council (IFIC) Michael Gruber Elinor Hitchner GMA Bayer HealthCare Miriam Guggenheim Sue Hite Covington & Burling LLP Military Contractor Tracey Halliday Jason Hlywka ABA Kraft Foods, Inc. Amy Hancock Rebecca Holmes ABA Red Bull North America Eileen Harley Judy Hong The Hershey Co. Goldman Sachs Molly Harry Joe Hovermill FDA Miles & Stockbridge Aubri Hazlett Terry Hughes J.M. Smucker Co. Monster Energy Co. Alix Heard Brokini Ibukunola Office of Rep. Frank Pallone Super Expedite Contractors Ltd.

APPENDIX B 179 Mark Itzkoff Chor San Khoo Olsson Frank Weeda Terman IFIC Matz PC Rick Kingston Michael Jacobson University of Minnesota Center for Science in the Public Interest (CSPI) Barbara Kochanowski Consumer Healthcare Products David Jaffe Association APCO Worldwide Nicole Kostelnick Sumitha Jagadibabu Campbell Soup Co. SIET College for Women Alison Kretser Diana Jeffery ILSI Daniel Johnston Steve Kuo Donnamaria Jones Taipei Economic and Cultural USUHS Representative Office Nicholas Kadysh Dorothy Lagg Mars, Inc. Saad Kamal Washington Analysis Barbara Larkin Kellogg’s Mark Kantor FDA Jae Lee Morrison & Foerster LLP Subhashini Katumuluwa NIH Ji-Eun Lee Kellogg’s Wanda Kelker The Coca-Cola Co. Shannon Leeke GMA Brian Kennedy GMA Lisa Lefferts CSPI Gerry Khermouch Beverage Business Insights

180 CAFFEINE IN FOOD AND DIETARY SUPPLEMENTS DeAnn Liska Sharon Mayl Kellogg’s FDA Craig Llewellyn Aileen McGrath The Coca-Cola Co. San Francisco City Attorney’s Office Emilia Lonardo GMA Carolyn Meduski Nestlé USA Lindsey Loving IFIC Carla Mejia U.S. Pharmacopeia (USP) Stefano Luccioli FDA Jeremy Mihalov FDA Zhelin Luo Washington University Farida Mohamedshah Institute of Food Technologists Maricel Maffini The Pew Charitable Trusts Amber Mosher HHS James Mann Newsmith Victoria Muldrow-Greene Walgreens Padma Maruvada NIH Jeff Mundt Hershey Arlene Mathes-Scharf Kashrut.com Jay Murray Murray & Associates Robert Mathews Keller and Heckman George Muscat Campbell Soup Co. Antonia Mattia FDA John Mwangi Starbucks Coffee Co. Jason May Rockstar, Inc.

APPENDIX B 181 Marianna Naum Rachel Poole FDA Temple University Emily Newman Lauren Pratapas Sidley Austin LLP Justin Prochnow Karlheinz Niederreiter Greenberg Traurig Red Bull GmbH Lucy Reid Inge Lise Nielsen Coca-Cola North America Bayer Consumer Care Amy Rinaldo Maria Fernanda Nunez Oakland Law Group University of Toronto Alberto Rivera-Rentas Claudia Nunn NIH Burdock Group Danielle Robertson Julie Obbagy Beachbody USDA Bob Roehr Hellen Oketch-Rabah British Medical Journal USP Sarah Romotsky Stephen Ostroff IFIC FDA Leah Rosenfeld Stuart Pape Patton FDA Boggs LLP Lauren Rossen Jennifer Person-Whippo Centers for Disease Control and Naval Supply Systems Prevention (CDC) Command Joel Rotstein Elyse Petroni Health Canada Story Partners Sylvia Rowe Laura Pillsbury SR StrategyJaclyn Royer GMA FDA

182 CAFFEINE IN FOOD AND DIETARY SUPPLEMENTS Marvin Rubin Jay Sirois Ohio Public Health Association Certified Healthcare Protection Administrators Allen Rudman FDA Kira Slagle Optimum Health Solutions, Inc. Helene Rutledge AeroDesigns, Inc. Rebecca Slater Podesta Group Kari Ryan Kraft Foods Kelly Smith Dr Pepper Snapple Group Rodney Sacks Monster Beverage Corporation Rob Smith Capital Alpha Partners Leila Saldanha NIH Meena Somanchi USDA Kathleen Sanzo Morgan Lewis & Bockius Barbara Sorkin NIH Nandakumara Sarma USP Tara Steeley Office of the City Attorney of Elyse Sartor San Francisco NIH Dan Steffen Phil Saul A-D Policy Analysis University of South Carolina Mark Stephens Hilton Schlosberg USUHS Monster Energy Co. Eve Essery Stoody Marilyn Schorin USDA Schorin Strategics, LLC Melissa Stringfellow Laura Shumow FDA National Confectioners Association Amy Sunderman Reckitt Benckiser

APPENDIX B 183 Christine Swanson Tom Vollmuth NIH Wrigley, Inc. Stanley Tarka Brian Waldman The Tarka Group, Inc. Arent Fox LLP Donna Thede Taylor Wallace Kellogg’s National Osteoporosis Foundation Janet Thorlton Purdue University Isabel Walls USDA Lisa Thorsten Campbell Soup Co. Brenda Watson Nestlé Nutrition Canada Lorna Totman Lorna Totman Consulting, LLC Cara Welch Natural Products Association Ken Trombetta Hoplite Capital Management Ann Wennberg Abbott Nutrition Pepin Tuma AND Nancy Wesensten Walter Reed Army Institute of Shashwat Udit Research Broadwood Capital Alex Wohl Pat Vanderkooy FDA Dietitians of Canada John White Patricia Vaughan ABA Arthur Whitmore FDA Laura Venker Keller & Heckman, LLP Joe Wilson UBS Marie Vicinanzo Novartis Consumer Health Kimberly Wingfield GMA

184 CAFFEINE IN FOOD AND DIETARY SUPPLEMENTS Nancy Yanish Jeffrey Zhao FDA ILSI North America Sam Zeller Gary Zizka Unilever Olsson Frank Weeda Terman Matz PC

Next: Appendix C: Biographical Sketches of Workshop Speakers and Moderators »
Caffeine in Food and Dietary Supplements: Examining Safety: Workshop Summary Get This Book
×
Buy Paperback | $54.00 Buy Ebook | $43.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Caffeine in Food and Dietary Supplements is the summary of a workshop convened by the Institute of Medicine in August 2013 to review the available science on safe levels of caffeine consumption in foods, beverages, and dietary supplements and to identify data gaps. Scientists with expertise in food safety, nutrition, pharmacology, psychology, toxicology, and related disciplines; medical professionals with pediatric and adult patient experience in cardiology, neurology, and psychiatry; public health professionals; food industry representatives; regulatory experts; and consumer advocates discussed the safety of caffeine in food and dietary supplements, including, but not limited to, caffeinated beverage products, and identified data gaps.

Caffeine, a central nervous stimulant, is arguably the most frequently ingested pharmacologically active substance in the world. Occurring naturally in more than 60 plants, including coffee beans, tea leaves, cola nuts and cocoa pods, caffeine has been part of innumerable cultures for centuries. But the caffeine-in-food landscape is changing. There are an array of new caffeine-containing energy products, from waffles to sunflower seeds, jelly beans to syrup, even bottled water, entering the marketplace. Years of scientific research have shown that moderate consumption by healthy adults of products containing naturally-occurring caffeine is not associated with adverse health effects. The changing caffeine landscape raises concerns about safety and whether any of these new products might be targeting populations not normally associated with caffeine consumption, namely children and adolescents, and whether caffeine poses a greater health risk to those populations than it does for healthy adults. This report delineates vulnerable populations who may be at risk from caffeine exposure; describes caffeine exposure and risk of cardiovascular and other health effects on vulnerable populations, including additive effects with other ingredients and effects related to pre-existing conditions; explores safe caffeine exposure levels for general and vulnerable populations; and identifies data gaps on caffeine stimulant effects.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!